GENETIC, VIRAL & IMMUNOLOGIC STUDIES IN NEW ZEALAND MICE

遗传、病毒

基本信息

  • 批准号:
    7186723
  • 负责人:
  • 金额:
    $ 33.45万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1979
  • 资助国家:
    美国
  • 起止时间:
    1979-07-01 至 2009-02-28
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The objectives are to understand why the lupus immune system responds abnormally to nucleosomes, the major products of physiologically programmed apoptosis, and how can such autoimmune responses be specifically down-regulated? Identification of the dominant epitopes in nucleosomes critical for cognate interactions between autoimmune T helper (Th) cells and anti-DNA B cells of lupus provided us the essential tools for two novel discoveries leading to the proposed experiments. 1). It is widely believed that negative selection is intact in lupus. We have now found that the thymuses of lupus-prone mice are unable to delete transgenic thymocytes bearing nucleosome-specific T-cell receptor (TCR), although central tolerance for other antigens is intact. For the first time, mechanism/s of this peculiarly selective defect in central tolerance for nucleosomes in the lupus-prone thymus will be defined using new lines of TCR-transgenic mice we have generated. Mice of normal backgrounds bearing the transgenes will be studied first to define mechanism/s of negative selection of T cells specific for nucleosomes, the major products of ongoing apoptosis in the thymus, and to define the spectrum of negatively selecting epitopes. Novel mechanisms of peripheral tolerance in these new transgenic mice bearing lupus TCR will also be studied, particularly a functional uncoupling of signaling by autoimmune TCR from full T cell activation. 2). We have found that therapeutic tolerance with very low doses of select nucleosomal peptides can down-regulate active lupus by unique mechanisms. The critical epitopes that are recognized in MHC unrestricted manner by pathogenic autoantibody-inducing Th cells of lupus are also recognized by autoimmune B cells, and such shared epitopes are potent tolerogens for therapy. We will determine how pathogenic autoantibody inducing help is impaired by very low-dose vs. high-dose tolerance therapy with the nucleosomal peptide epitope/s we have identified, a). Role of anergy or deletion of lupus T and B cells; b). role of long-lasting regulatory (suppressor) T cell subsets with unique markers that are generated by peptide therapy; and c). the roles of tolerogenic dendritic cells and B cells in the generation of unusual regulatory T cells will be defined. The studies will address fundamental questions regarding autoimmunity and tolerance to an ubiquitous product of apoptosis, and would help in developing antigen-specific therapy of lupus.
描述(由申请人提供):

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

SYAMAL K DATTA其他文献

SYAMAL K DATTA的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('SYAMAL K DATTA', 18)}}的其他基金

IMMUNE MECHANISMS OF ANTICD40L TRIAL IN SLE
SLE 中 ANTICD40L 试验的免疫机制
  • 批准号:
    2882256
  • 财政年份:
    1999
  • 资助金额:
    $ 33.45万
  • 项目类别:
IMMUNE MECHANISMS OF ANTICD40L TRIAL IN SLE
SLE 中 ANTICD40L 试验的免疫机制
  • 批准号:
    6137339
  • 财政年份:
    1999
  • 资助金额:
    $ 33.45万
  • 项目类别:
IMMUNE MECHANISMS OF ANTICD40L TRIAL IN SLE
SLE 中 ANTICD40L 试验的免疫机制
  • 批准号:
    6341792
  • 财政年份:
    1999
  • 资助金额:
    $ 33.45万
  • 项目类别:
SEARCH FOR NOVEL B CELL HYPERACTIVITY GENES
寻找新型 B 细胞过度活跃基因
  • 批准号:
    6100391
  • 财政年份:
    1998
  • 资助金额:
    $ 33.45万
  • 项目类别:
SEARCH FOR NOVEL B CELL HYPERACTIVITY GENES
寻找新型 B 细胞过度活跃基因
  • 批准号:
    6235685
  • 财政年份:
    1997
  • 资助金额:
    $ 33.45万
  • 项目类别:
SEARCH FOR NOVEL B CELL HYPERACTIVITY GENES
寻找新型 B 细胞过度活跃基因
  • 批准号:
    6268330
  • 财政年份:
    1997
  • 资助金额:
    $ 33.45万
  • 项目类别:
MECHANISM OF AUTOIMMUNE RESPONSE IN HUMAN LUPUS
人类狼疮的自身免疫反应机制
  • 批准号:
    2748628
  • 财政年份:
    1993
  • 资助金额:
    $ 33.45万
  • 项目类别:
MECHANISM OF AUTOIMMUNE RESPONSE IN HUMAN LUPUS
人类狼疮的自身免疫反应机制
  • 批准号:
    2457949
  • 财政年份:
    1993
  • 资助金额:
    $ 33.45万
  • 项目类别:
MECHANISM OF AUTOIMMUNE RESPONSE IN HUMAN LUPUS
人类狼疮的自身免疫反应机制
  • 批准号:
    6043194
  • 财政年份:
    1993
  • 资助金额:
    $ 33.45万
  • 项目类别:
MECHANISM OF AUTOIMMUNE RESPONSE IN HUMAN LUPUS
人类狼疮的自身免疫反应机制
  • 批准号:
    6374902
  • 财政年份:
    1993
  • 资助金额:
    $ 33.45万
  • 项目类别:

相似国自然基金

Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
  • 批准号:
    2022J011295
  • 批准年份:
    2022
  • 资助金额:
    10.0 万元
  • 项目类别:
    省市级项目
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究
  • 批准号:
    30801055
  • 批准年份:
    2008
  • 资助金额:
    19.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Bovine herpesvirus 4 as a vaccine platform for African swine fever virus antigens in pigs
牛疱疹病毒 4 作为猪非洲猪瘟病毒抗原的疫苗平台
  • 批准号:
    BB/Y006224/1
  • 财政年份:
    2024
  • 资助金额:
    $ 33.45万
  • 项目类别:
    Research Grant
Uncovering tumor specific antigens and vulnerabilities in ETP-acute lymphoblastic leukemia
揭示 ETP-急性淋巴细胞白血病的肿瘤特异性抗原和脆弱性
  • 批准号:
    480030
  • 财政年份:
    2023
  • 资助金额:
    $ 33.45万
  • 项目类别:
    Operating Grants
A novel vaccine approach combining mosquito salivary antigens and viral antigens to protect against Zika, chikungunya and other arboviral infections.
一种结合蚊子唾液抗原和病毒抗原的新型疫苗方法,可预防寨卡病毒、基孔肯雅热和其他虫媒病毒感染。
  • 批准号:
    10083718
  • 财政年份:
    2023
  • 资助金额:
    $ 33.45万
  • 项目类别:
    Small Business Research Initiative
Regulation of B cell responses to vaccines by long-term retention of antigens in germinal centres
通过在生发中心长期保留抗原来调节 B 细胞对疫苗的反应
  • 批准号:
    MR/X009254/1
  • 财政年份:
    2023
  • 资助金额:
    $ 33.45万
  • 项目类别:
    Research Grant
Adaptive Discrimination of Risk of Antigens in Immune Memory Dynamics
免疫记忆动态中抗原风险的适应性辨别
  • 批准号:
    22KJ1758
  • 财政年份:
    2023
  • 资助金额:
    $ 33.45万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
22-ICRAD Call 2 - Improving the diagnosis of tuberculosis in domestic ruminants through the use of new antigens and test platforms
22-ICRAD 呼吁 2 - 通过使用新抗原和测试平台改善家养反刍动物结核病的诊断
  • 批准号:
    BB/Y000927/1
  • 财政年份:
    2023
  • 资助金额:
    $ 33.45万
  • 项目类别:
    Research Grant
Protective immunity elicited by distinct polysaccharide antigens of classical and hypervirulent Klebsiella
经典和高毒力克雷伯氏菌的不同多糖抗原引发的保护性免疫
  • 批准号:
    10795212
  • 财政年份:
    2023
  • 资助金额:
    $ 33.45万
  • 项目类别:
Integrative proteome analysis to harness humoral immune response against tumor antigens
综合蛋白质组分析利用针对肿瘤抗原的体液免疫反应
  • 批准号:
    23K18249
  • 财政年份:
    2023
  • 资助金额:
    $ 33.45万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
Functionally distinct human CD4 T cell responses to novel evolutionarily selected M. tuberculosis antigens
功能独特的人类 CD4 T 细胞对新型进化选择的结核分枝杆菌抗原的反应
  • 批准号:
    10735075
  • 财政年份:
    2023
  • 资助金额:
    $ 33.45万
  • 项目类别:
Targeting T3SA proteins as protective antigens against Yersinia
将 T3SA 蛋白作为针对耶尔森氏菌的保护性抗原
  • 批准号:
    10645989
  • 财政年份:
    2023
  • 资助金额:
    $ 33.45万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了